Skip to main content
Egyptian Journal of Radiology and Nuclear Medicine
Fig. 6 | Egyptian Journal of Radiology and Nuclear Medicine

Fig. 6

From: Role of 18 fluorine-fluorodeoxyglucose positron emission tomography/computed tomography in assessment of neoadjuvant chemotherapy response in breast cancer patients

Fig. 6

56 years old female patient with history of left breast cancer, submitted for MRM followed by chemotherapy and hormonal treatment, presented with focal skin thickening at the operative bed, and histopathologicaly proven to be recurrent neoplasia (IDC basal subtype-tripple negative). Axial CECT and fused PET/CT images (a, b) revealed metabolically active soft tissue mass lesion measuring about 15 × 46 mm and achieving 3.4 SULpeak. On follow-up after completion of chemotherapy, the lesion shows regression in size (measuring 19 × 29 mm) in axial CECT (c) denotin partial response, yet with progression in FDG uptake (achieving 6.4 SULpeak) in fused PET/CT image (d) denoting progressive metabolic disease

Back to article page